Qol Medcl Drug Patent Portfolio
Qol Medcl owns 2 orange book drugs protected by 11 US patents Given below is the list of Qol Medcl's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12377064 | Treatment Of Moderate And Severe Gastroparesis | 17 Nov, 2038 | Active |
| US9255261 | Ultrapure hypoallergenic solutions of sacrosidase | 07 Feb, 2034 | Active |
| US9469847 | Ultrapure hypoallergenic solutions of sacrosidase | 07 Feb, 2034 | Active |
| US9849161 | Ultrapure hypoallergenic solutions of sacrosidase | 07 Feb, 2034 | Active |
| US8334281 | Nasal formulations of metoclopramide | 16 May, 2030 | Active |
| US11020361 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US11628150 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US11813231 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US12194008 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US12194009 | Nasal formulations of metoclopramide | 22 Dec, 2029 | Active |
| US6770262 | Nasal administration of agents for the treatment of gastroparesis | 29 Mar, 2021 | Expired |
Latest Legal Activities on Qol Medcl's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Qol Medcl.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 12 Aug, 2025 | US12377064 |
| Patent Issue Date Used in PTA Calculation | 05 Aug, 2025 | US12377064 |
| Mail Patent eGrant Notification | 05 Aug, 2025 | US12377064 |
| Patent eGrant Notification | 05 Aug, 2025 | US12377064 |
| Email Notification | 05 Aug, 2025 | US12377064 |
| Recordation of Patent eGrant | 05 Aug, 2025 | US12377064 |
| Email Notification | 24 Jul, 2025 | US12377064 |
| Issue Notification Mailed | 23 Jul, 2025 | US12377064 |
| Dispatch to FDC | 10 Jul, 2025 | US12377064 |
| Application Is Considered Ready for Issue | 10 Jul, 2025 | US12377064 |
| Issue Fee Payment Verified | 07 Jul, 2025 | US12377064 |
| Issue Fee Payment Received | 07 Jul, 2025 | US12377064 |
| Mail Notice of Allowance | 01 Jul, 2025 | US12377064 |
| Notice of Allowance Data Verification Completed | 30 Jun, 2025 | US12377064 |
| Date Forwarded to Examiner | 12 Jun, 2025 | US12377064 |
Qol Medcl's Family Patents
Qol Medcl Drug List
Given below is the complete list of Qol Medcl's drugs and the patents protecting them.
1. Gimoti
Gimoti is protected by 8 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12377064 | Treatment Of Moderate And Severe Gastroparesis |
17 Nov, 2038
(12 years from now)
| Active |
| US8334281 | Nasal formulations of metoclopramide |
16 May, 2030
(4 years from now)
| Active |
| US11020361 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US11628150 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US11813231 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US12194008 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US12194009 | Nasal formulations of metoclopramide |
22 Dec, 2029
(3 years from now)
| Active |
| US6770262 | Nasal administration of agents for the treatment of gastroparesis |
29 Mar, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gimoti's drug page
2. Sucraid
Sucraid is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9255261 | Ultrapure hypoallergenic solutions of sacrosidase |
07 Feb, 2034
(7 years from now)
| Active |
| US9469847 | Ultrapure hypoallergenic solutions of sacrosidase |
07 Feb, 2034
(7 years from now)
| Active |
| US9849161 | Ultrapure hypoallergenic solutions of sacrosidase |
07 Feb, 2034
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sucraid's drug page